Gene-Edited immune cells take on autoimmune blood diseases
NCT ID NCT07549698
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 4 times
Summary
This early-stage trial tests a one-time treatment called CTX112, made from donor immune cells edited with CRISPR technology. It aims to safely control two autoimmune diseases where the body attacks its own blood cells: immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). About 60 adults who have not responded to standard therapies will receive an infusion of these engineered cells and be monitored for side effects and signs of disease improvement.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIC PURPURA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gregorio Marañón General University Hospital
RECRUITINGMadrid, Spain
Contact
-
Hospital Universitario La Paz
NOT_YET_RECRUITINGMadrid, Spain
Contact
-
Hospital Universitario Reina Sofia
RECRUITINGCórdoba, 14004, Spain
Contact
-
Hospital Universitario Virgen del Rocio
RECRUITINGSeville, Spain
Contact
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
-
Medizinische Hochschule Hannover
NOT_YET_RECRUITINGHannover, Germany
Contact
-
Medizinische Hochschule Hannover (MHH)
NOT_YET_RECRUITINGHanover, 30625, Germany
Contact
-
UCT University Medical Center Mainz
NOT_YET_RECRUITINGMainz, 55131, Germany
Contact
-
Universitaetsklinikum Koeln
RECRUITINGCologne, Germany
Contact
-
University of Nebraska Medical Center
RECRUITINGOmaha, Nebraska, 68198, United States
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug ANX005 targets blood cell destruction in autoimmune anemia
- Could a cholesterol drug and antioxidant help treat a rare bleeding disorder?
- New combo therapy aims to boost platelets in ITP patients
- Can a simple blood test predict who will get chronic ITP?
- New pill could help patients with rare blood disorder
- New drug IASO-782 aims to tame immune attacks on blood cells